Shield Therapeutics plc (AIM:STX)

Shield Therapeutics Ratios and Metrics

Market cap in millions GBP. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 22, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	115	21	52	18	96	75
Market Cap Growth	459.17%	-59.70%	186.53%	-80.96%	28.62%	-64.39%
Enterprise Value	127	31	46	16	73	68
Last Close Price	0.11	0.03	0.07	0.07	0.43	0.60
PS Ratio	3.79	0.82	5.10	4.01	63.24	7.19
PB Ratio	-10.59	-20.07	4.44	3.37	2.36	2.47
P/TBV Ratio	-	-	4.82	4.15	4.11	6.53
P/FCF Ratio	31.13	-	-	-	-	-
P/OCF Ratio	31.12	-	-	-	-	-
EV/Sales Ratio	4.18	1.19	4.50	3.48	48.36	6.56
EV/EBITDA Ratio	-	-	-	-	-	2840.59
EV/FCF Ratio	34.34	-	-	-	-	-
Debt / Equity Ratio	-1.82	-20.02	1.35	1.04	0.00	0.00
Debt / EBITDA Ratio	-	-	-	-	-	1.17
Debt / FCF Ratio	5.35	-	-	-	-	-
Asset Turnover	0.76	0.61	0.35	0.14	0.04	0.30
Inventory Turnover	3.98	3.89	3.65	1.63	0.65	1.16
Quick Ratio	0.69	0.90	1.83	0.62	3.73	1.60
Current Ratio	0.83	1.16	2.28	0.95	4.64	2.32
Return on Equity (ROE)	-	-396.36%	-308.60%	-179.19%	-55.46%	-8.43%
Return on Assets (ROA)	-16.77%	-26.90%	-51.93%	-49.37%	-32.97%	-3.91%
Return on Capital Employed (ROCE)	-120.80%	-92.00%	-89.40%	-229.50%	-49.90%	-7.10%
Earnings Yield	-13.50%	-102.83%	-49.88%	-225.97%	-20.48%	-3.52%
FCF Yield	3.21%	-25.74%	-55.98%	-102.82%	-19.40%	-1.87%
Buyback Yield / Dilution	-19.74%	-8.33%	-209.85%	-14.08%	-74.36%	-0.21%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.